MedTrace Logo

Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer

NCT05468554 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-10-19

No results posted yet for this study

Summary

This study is aimed to investigate the metformin effect on the fertility of women treated with 131 I for thyroid cancer

Conditions

Interventions

DRUG

metformin

Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.

RADIATION

Radioactive iodine (I-131)

Patients qualified to receive 131I treatment

Sponsors & Collaborators

  • Medical Research Agency, Poland

    collaborator OTHER_GOV

  • Medical University of Bialystok

    lead OTHER

Principal Investigators

  • Agnieszka Adamska, Assoc.Prof. · Medical University of Bialystok

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05468554 on ClinicalTrials.gov